

Materials for this course will release 04/13/2022

Pediatric Pharmacy Specialty Recertification Literature Study: Module 1A-B (Cert # L229114)

Teaser: The Literature Study Module provides immediate access to peer-selected, contemporary articles that are relevant to specialty practice. After learners review the content, they must successfully complete an online assessment to earn recertification credit.

Tag: Certifications; Pediatrics



ACPE Numbers: Various – see listing below

Pre-Sale Date: 03/16/2022

Content Release Date: 04/13/2022

Expiration Dates: 10/18/2022

Activity Type: Application-based

CE Credits: 10 contact hours

Activity Fee: \$55 (ASHP member); \$110 (non-member)

Accreditation for Pharmacists



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours to maintain their Board of Pharmacy Specialties (BPS).

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners' ability to analyze and apply peer-selected contemporary articles to practice and includes a short video for enhanced learning and understanding.

Module 1A: Hematology/Oncology: This module focuses on pediatric hematology and oncology issues such as febrile neutropenia, nodular desmoplastic medulloblastoma, nelarabine for acute lymphoblastic leukemia, high-risk neuroblastoma and guidelines for sickle cell disease.

Module 1B: Neonate: This module focuses on neonatal issues such as aerosilized calfactant for respiratory distress, new approach to recognize impaired kidney function, opioid withdrawal syndrome and use of probiotics.

Materials for this course will release 04/13/2022

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 10 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity	ACPE Number	Contact Hours	Assessment Pass Point
Pediatric Pharmacy Literature Study Module 1A: Hematology/Oncology	0204-0000-22-942-H01-P	6.00	TBD
Pediatric Pharmacy Literature Study Module 1B: Neonate	0204-0000-22-943-H01-P	4.00	TBD
Recertification Assessment Group 1		10.0 BPS	

Articles and Learning Objectives

Pediatric Pharmacy Literature Study Module 1A: Hematology/Oncology

ACPE Number: 0204-0000-22-942-H01-P

Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv (2020) 4 (12): 2656–2701.

<https://doi.org/10.1182/bloodadvances.2020001851>

Learning Objectives:

- Describe the American Society of Hematology (ASH) 2020 guidelines for the management of acute and chronic pain in patients with sickle cell disease (SCD).
- Develop recommendations for managing acute and chronic pain in patients with sickle cell disease (SCD).
- Identify limitations to the current ASH guidelines and opportunities for future research.

Materials for this course will release 04/13/2022

Avilés-Robles MJ, Reyes-López A, Otero-Mendoza FJ, et al. Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial. *Pediatr Blood Cancer*. 2020 Jun;67(6):e28251. doi: 10.1002/pbc.28251. Epub 2020 Mar 20. PMID: 32196898.

Learning Objectives:

- Describe the study by Avilés-Robles and colleagues comparing early step-down to oral outpatient antimicrobial treatment with conventional inpatient intravenous antimicrobial treatment for pediatric cancer patients with low-risk febrile neutropenia.
- Develop recommendations for the use of antimicrobial therapy for pediatric cancer patients with low-risk febrile neutropenia.

Dhall G, O'Neil SH, Ji L, et al. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial. *Neuro Oncol*. 2020 Dec 18;22(12):1862-1872. doi: 10.1093/neuonc/noaa102. PMID: 32304218; PMCID: PMC7746930.

Learning Objectives:

- Describe the "Head Start" III study by Dhall and colleagues of young children with medulloblastoma.
- Develop recommendations for the treatment of young children with medulloblastoma.

Dunsmore KP, Winter SS, Devidas M, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. *J Clin Oncol*. 2020 Oct 1;38(28):3282-3293. doi: 10.1200/JCO.20.00256. Epub 2020 Aug 19. PMID: 32813610; PMCID: PMC7526719.

Learning Objectives:

- Describe the Children's Oncology Group trial AALL0434 by Dunsmore and colleagues of nelarabine in patients with newly-diagnosed T-cell acute lymphoblastic leukemia (T-ALL).
- Develop recommendations for the use of nelarabine in patients with newly-diagnosed T-cell acute lymphoblastic leukemia (T-ALL).

Mora J, Castañeda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. *Pediatr Blood Cancer*. 2021 May 22:e29121. doi: 10.1002/pbc.29121. Epub ahead of print. PMID: 34022112.

Learning Objectives:

- Describe the study by Mora and colleagues of naxitamab combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) as consolidation for patients with high-risk neuroblastoma in complete remission.
- Develop recommendations for the use of naxitamab combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) as consolidation for patients with high-risk neuroblastoma in complete remission.

Materials for this course will release 04/13/2022

Pediatric Pharmacy Literature Study Module 1B: Neonate

ACPE Number: 0204-0000-22-943-H01-P

Cummings JJ, Gerday E, Minton S, et al. Aerosolized calfactant for newborns with respiratory distress: a randomized trial. *Pediatrics*. 2020 Nov;146(5):e20193967. doi: 10.1542/peds.2019-3967. Epub 2020 Oct 15. PMID: 33060258.

Learning Objectives:

- Describe the study by Cummings and colleagues of aerosolized calfactant in newborn infants with mild-to-moderate respiratory distress.
- Develop recommendations for the use of aerosolized calfactant in newborn infants with mild-to-moderate respiratory distress.

Perazzo S, Revenis M, Massaro A, Short BL, Ray PE. A New Approach to Recognize Neonatal Impaired Kidney Function. *Kidney Int Rep*. 2020 Oct 3;5(12):2301-2312. doi: 10.1016/j.ekir.2020.09.043. PMID: 33305124; PMCID: PMC7710891.

Learning Objectives:

- Describe the study by Perazzo and colleagues of a method for detecting impaired kidney function (IKF) in critically ill neonates.
- Develop recommendations for the detection of impaired kidney function (IKF) in critically ill neonates.

Patrick SW, Barfield WD, Poindexter BB; COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON SUBSTANCE USE AND PREVENTION. Neonatal Opioid Withdrawal Syndrome. *Pediatrics*. 2020 Nov;146(5):e2020029074. doi: 10.1542/peds.2020-029074. PMID: 33106341.

Learning Objectives:

- Describe the American Academy of Pediatrics (AAP) statement on neonatal opioid withdrawal syndrome (NOWS), including recent trends and the clinical presentation, assessment, and treatment of the syndrome.
- Develop recommendations for the management of neonatal opioid withdrawal syndrome (NOWS).

Poindexter B; COMMITTEE ON FETUS AND NEWBORN. Use of Probiotics in Preterm Infants. *Pediatrics*. 2021 Jun;147(6):e2021051485. doi: 10.1542/peds.2021-051485. Epub 2021 May 24. PMID: 34031231.

Learning Objectives:

- Describe the differences among commercially available probiotic preparations, regulatory standards governing their use in the United States, potential risks associated with the use of probiotics, and currently available evidence of their efficacy and safety for the prevention and treatment of necrotizing enterocolitis (NEC) and late-onset sepsis in preterm infants.
- Develop recommendations for the use of probiotics in preterm infants.

Materials for this course will release 04/13/2022

Faculty

Zanette Kanani Bradley, Pharm.D., BCOP
Pediatric Oncology Clinical Pharmacist
Children's Hospital Colorado
Aurora, Colorado

Austyn Grim, Pharm.D., BCPPS
Clinical Pharmacy Specialist - Pediatric
Oncology/BMT
Texas Children's Hospital
Houston, Texas

Nicole Palazzolo, Pharm.D., BCPPS
NICU Clinical Pharmacist
UVA Children's Hospital
Charlottesville, Virginia

Kynlon Phillips, Pharm.D., BCOP, BCPS, CPP
Clinical Pharmacist Practitioner, UNC Pediatric
Hematology/Oncology Clinic
101 Manning Drive, CB# 7600
Chapel Hill, North Carolina

Ashley Sabus, Pharm.D., BCOP
Clinical Pharmacy Specialist - Pediatric
Oncology/Bone Marrow Transplant
Texas Children's Hospital
Houston, Texas

Pooja Shah, Pharm.D., BCPPS
Clinical Associate Professor, Ernest Mario School of
Pharmacy
Rutgers University, The State University of New
Jersey
Piscataway, New Jersey

Content Matter Experts

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM,
FPPAG
Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Jamie L. Miller, Pharm.D., BCPPS, BCPS, FPPAG
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Jennifer Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

Reviewers

Michelle C. Abalos, Pharm.D.
Susan R. Dombrowski, B.S.Pharm., M.S.

Field Testers

Hakeem Abayomi, B.S., Pharm.D., BCPS, BCPPS, BCIDP
Renad Abu-Sawwa, Pharm.D. BCPPS
Leanna Barker, Pharm.D., BCPPS
Samantha Brokenshire, Pharm.D., BCPPS
Darrin Dillingham, Pharm.D.
Alexandra Fife, Pharm.D., BCPPS
Aaron Harthan, Pharm.D., BCPPS
Christina Hellauer, Pharm.D., BCPPS

Pui Man (Julia) Ho, Pharm.D., BCPPS
Melissa Hunt, Pharm.D., BCPPS
Holly Kaminski, B.S.Pharm, BCPS, BCPPS
Jin Kim, Pharm.D., BCPPS
Kelly Kopec, Pharm.D. BCPPS
Thomas Laudone, Pharm.D., BCPPS
Fangchen Lin, Pharm.D., BCPPS
Kristin Luckeroth, Pharm.D., BCPPS

Materials for this course will release 04/13/2022

Justin McCord, Pharm.D., BCPPS
Cody Moseman, Pharm.D., BCPPS
Erin Munsel, Pharm.D., BCPPS
Christian Nicolosi, Pharm.D., BCPPS
Lucas Orth, Pharm.D., BCPPS
Seema Patel, Pharm.D., BCPPS, APHa
Kevin Poel, Pharm.D., BCPPS

Tamara Potter, Pharm.D., BCPPS
Mike Raschka, Pharm.D., BCPPS
Anna Simmont, Pharm.D., BCPS, BCPPS
Lindsay Villalobos, Pharm.D., BCPPS
Marry Vuong, Pharm.D., BCPPS
Ryan Wozniewicz, Pharm.D., BCPPS

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

All other planners, presenters, reviewers, ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

Development

These activities were developed by ASHP.